Pharmacogenomics in bladder cancer

This publication has 52 references indexed in Scilit:

• ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings
  European Urology, 2013
• Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
  Nucleic Acids Research, 2012
• The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
  Nature, 2012
• Biomarkers for prognosis and treatment selection in advanced bladder cancer patients
  Current Opinion in Urology, 2011
• Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
  Cancer Treatment Reviews, 2007
• A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery
  Proceedings of the National Academy of Sciences, 2007
• Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
  British Journal of Cancer, 2007
• Molecular mechanisms of resistance and toxicity associated with platinating agents
  Cancer Treatment Reviews, 2007
• Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
  Annals of Oncology, 2007
• Cisplatin: mode of cytotoxic action and molecular basis of resistance
  Oncogene, 2003